If you find this podcast useful please give it a rating and review on iTunes by clicking here
Roby Zomer, Managing Director & CEO & Rob Clements, Chief Commercial Officer of MGC Pharmaceuticals explains how the availability of CannEpil® by Named Patient Request in the UK marks a momentous breakthrough for the company.
Highlights
· CannEpil®, MGC Pharma's Investigational Medicinal Product ("IMP") is now available in the United Kingdom by Named Patient Request to be prescribed by doctors on The General Medical Council ("GMC") specialist register across the UK.
· The products will be supplied in order to meet the needs of an individual patients where an unmet medical need exists.
· The availability via Named Patient Request follows the announcement that MGC Pharma is providing CannEpil® to an observational trial supported by the I am Billy Foundation.
· CannEpil® is in the process of a clinical development programme for patients suffering from Refractory (or Drug-Resistant) Epilepsy.